Immune responses elicited by apoB-100-derived peptides in mice

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Immunologic research

• Publication date

  2013-01-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12026-013-8383-1PMID 23345063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis

  2010cited by this paper
• Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions.

  2009cited by this paper
• 2. Dendritic cells as regulators of immunity and tolerance.

  2008cited by this paper
• Revival of CD8+ Treg-mediated suppression.

  2008cited by this paper
• Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients.

  2008cited by this paper
• Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice

  2008cited by this paper
• Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B‐100 transgenic mice without inducing an increase in peptide‐specific antibodies

  2008cited by this paper
• Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

  2008cited by this paper
• Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice.

  2008cited by this paper
• Mechanisms and consequences of dendritic cell migration.

  2008cited by this paper
• Autoimmunity in atherosclerosis: a protective response losing control?

  2008cited by this paper
• Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

  2008cited by this paper
• Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.

  2007cited by this paper
• OX40 costimulation turns off Foxp3+ Tregs.

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Immunoregulation: Enhancement of Regulatory T Cells through PPARγ-Dependent and -Independent Mechanisms

  2007cited by this paper
• CD4[+]CD25[+]Foxp3[+] T cells and CD4[+]CD25[-]Foxp3[+] T cells in aged mice

  2007cited by this paper
• Active and passive immunization for atherosclerosis.

  2007cited by this paper
• Inflammation and atherosclerosis.

  2006cited by this paper
• Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization

  2006cited by this paper
• CD4+CD25+Foxp3+ T Cells and CD4+CD25−Foxp3+ T Cells in Aged Mice1

  2006cited by this paper
• Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.

  2006cited by this paper
• Inflammation and Atherosclerosis

  2004cited by this paper
• Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression.

  2004cited by this paper
• CETi-1. AVANT.

  2004cited by this paper
• Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli.

  2004cited by this paper
• Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences

  2003cited by this paper
• The safety and immunogenicity of a CETP vaccine in healthy adults.

  2003cited by this paper
• Modulating the immune response with dendritic cells and their growth factors.

  2001cited by this paper
• IL-6 Inhibits the Tolerogenic Function of CD8α+ Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase1

  2001cited by this paper
• CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen1

  2000cited by this paper
• Dendritic cell regulation of TH1-TH2 development

  2000cited by this paper
• Immunological techniques made easy

  1998cited by this paper
• Analysis of the T cell receptor Vβ repertoire in human aortic aneurysms

  1997cited by this paper
• Analysis of the T cell receptor V beta repertoire in human aortic aneurysms.

  1997cited by this paper
• [8] Use of glutaraldehyde as a coupling agent for proteins and peptides

  1980cited by this paper
• Use of glutaraldehyde as a coupling agent for proteins and peptides.

  1980cited by this paper
• The use of carbodiimides in the preparation of immunizing conjugates.

  1980cited by this paper

• Immunology of atherosclerosis: problems and prospects of immunotherapy

  2025cites this paper
• Two decades of vaccine development against atherosclerosis.

  2023cites this paper
• Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis

  2022cites this paper
• Study on the domain selective inhibition of angiotensin-converting enzyme (ACE) by food-derived tyrosine-containing dipeptides.

  2021cites this paper
• Retinoic Acid-Loaded PLGA Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis

  2021cites this paper
• Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis.

  2020cites this paper
• Cryptic host defense peptides: multifaceted activity and prospects for medicinal chemistry.

  2020cites this paper
• CD8+ T Cells in Atherosclerosis

  2020cites this paper
• The many faces of CD8+ T cells in atherosclerosis

  2018cites this paper
• Antibody-mediated Immunity in Cardiovascular Disease

  2018cites this paper
• Apolipoprotein B containing lipoproteins contribute to host innate immune pulmonary defense against Staphylococcus aureus

  2018cites this paper
• An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice

  2017cites this paper
• Progress and future opportunities in the development of vaccines against atherosclerosis

  2017cites this paper
• T-Cells Specific for a Self-Peptide of ApoB-100 Exacerbate Aortic Atheroma in Murine Atherosclerosis

  2017cites this paper
• Assessment of Carrot Callus as Biofactories of an Atherosclerosis Oral Vaccine Prototype

  2017influential citation
• Novel human bioactive peptides identified in Apolipoprotein B: Evaluation of their therapeutic potential

  2017cites this paper
• Chlamydomonas reinhardtii chloroplasts express an orally immunogenic protein targeting the p210 epitope implicated in atherosclerosis immunotherapies

  2016cites this paper
• The role of T and B cells in human atherosclerosis and atherothrombosis

  2015cites this paper
• Vaccination to modulate atherosclerosis

  2015cites this paper
• Effects of apoB-derived peptide vaccination in a murine model of systemic lupus erythematosus

  2015cites this paper
• Apolipoprotein B containing lipoproteins contribute to host innate immune pulmonary defense against Staphylococcus aureus

  2015cites this paper
• Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential

  2015cites this paper
• Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses

  2014cites this paper
• Can We Vaccinate Against Atherosclerosis?

  2014cites this paper
• Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects

  2014cites this paper
• Innate immune system cells in atherosclerosis.

  2014cites this paper
• Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases

  2014cites this paper
• Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100

  2013cites this paper
• Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

  2013cites this paper
• WITHDRAWN: Dendritic cells: A double-edge sword in atherosclerotic inflammation.

  2013cites this paper
• Dendritic cells in cardiovascular diseases: epiphenomenon, contributor, or therapeutic opportunity.

  2013cites this paper
• Dendritic Cells: Conductors of Innate and Adaptive Immune Responses Dendritic Cells in Cardiovascular Diseases Epiphenomenon, Contributor, or Therapeutic Opportunity Basic Science for Clinicians

  year unknowncites this paper